SynthesisPloS one2014

48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.

Dipen A Patel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.